{
    "hands_on_practices": [
        {
            "introduction": "To understand the inflammatory response, we must quantify the relationship between the concentration of a chemical mediator and its physiological effect. This practice moves beyond qualitative descriptions by using the example of histamine-induced vascular permeability to introduce a powerful pharmacological model, helping you calculate how changes in mediator levels translate into a change in tissue response. ",
            "id": "4340897",
            "problem": "In acute inflammation, histamine released from mast cells binds Histamine H1 receptors (H1R) on postcapillary venular endothelium and increases permeability by contracting endothelial cells and opening intercellular junctions. Assume the following foundational principles: (i) receptor-mediated responses can be modeled by the Hill–Langmuir occupancy relation, in which fractional receptor occupancy is given by $$\\theta([H])=\\frac{[H]^{n}}{K_{d}^{n}+[H]^{n}},$$ where $[H]$ is the free histamine concentration, $K_{d}$ is the dissociation constant, and $n$ is the Hill coefficient capturing effective cooperativity of the integrated response; and (ii) when downstream transduction is effectively linear near the operating range, the physiological effect scales with occupancy as $$E([H])=E_{\\max}\\,\\theta([H]),$$ where $E_{\\max}$ is the maximum attainable increment in a dimensionless permeability index (normalized so that $E=0$ in the absence of histamine and $E=E_{\\max}$ at saturating histamine). For many G protein-coupled receptor systems under these assumptions, the half-maximal effective concentration $EC_{50}$ approximates $K_{d}$, so that $EC_{50}\\approx K_{d}$ is a well-tested operational parameter.\n\nA biopsy-based microdialysis study of an inflamed tissue records a baseline interstitial histamine concentration $[H]_{0}=0.50\\,\\mu\\text{M}$. A subsequent mast cell degranulation event doubles the local histamine to $[H]_{1}=1.00\\,\\mu\\text{M}$. For the venular permeability response in this tissue, take $E_{\\max}=1.50$ (dimensionless), $EC_{50}=0.75\\,\\mu\\text{M}$, and the effective Hill coefficient $n=2$.\n\nUsing the principles above, compute the fractional change in the permeability index relative to baseline, defined as $$\\Delta=\\frac{E([H]_{1})-E([H]_{0})}{E([H]_{0})}.$$ Express your final answer as a unitless decimal number, and round your answer to four significant figures.",
            "solution": "The problem statement is rigorously validated and found to be scientifically grounded, well-posed, objective, and internally consistent. It presents a standard biophysical modeling scenario based on the Hill–Langmuir equation, which is a cornerstone of quantitative pharmacology and receptor theory. The provided parameters for histamine concentration, $EC_{50}$, and Hill coefficient are within physiologically plausible ranges for receptor-mediated signaling. The problem is formalizable and requires a direct application of the given principles to compute a clear, uniquely defined quantity. Therefore, a complete solution is warranted.\n\nThe physiological effect, designated as the permeability index $E$, is a function of the histamine concentration $[H]$. It is given by the product of the maximum effect $E_{\\max}$ and the fractional receptor occupancy $\\theta([H])$:\n$$E([H]) = E_{\\max} \\, \\theta([H])$$\nThe fractional occupancy follows the Hill–Langmuir relation:\n$$\\theta([H]) = \\frac{[H]^{n}}{K_{d}^{n} + [H]^{n}}$$\nwhere $n$ is the Hill coefficient and $K_d$ is the dissociation constant. Combining these gives the full expression for the effect:\n$$E([H]) = E_{\\max} \\frac{[H]^{n}}{K_{d}^{n} + [H]^{n}}$$\nThe problem states that the half-maximal effective concentration $EC_{50}$ approximates the dissociation constant $K_d$. This is a common and reasonable operational assumption for systems where the biological response is linearly proportional to receptor occupancy. We therefore substitute $EC_{50}$ for $K_d$:\n$$E([H]) = E_{\\max} \\frac{[H]^{n}}{EC_{50}^{n} + [H]^{n}}$$\nWe are asked to compute the fractional change in the permeability index, $\\Delta$, as the histamine concentration increases from a baseline value of $[H]_{0} = 0.50\\,\\mu\\text{M}$ to a new value of $[H]_{1} = 1.00\\,\\mu\\text{M}$. The definition of $\\Delta$ is provided:\n$$\\Delta = \\frac{E([H]_{1}) - E([H]_{0})}{E([H]_{0})}$$\nThis can be rewritten as:\n$$\\Delta = \\frac{E([H]_{1})}{E([H]_{0})} - 1$$\nLet us now formulate the ratio $\\frac{E([H]_{1})}{E([H]_{0})}$. Using the expression for $E([H])$, we have:\n$$\\frac{E([H]_{1})}{E([H]_{0})} = \\frac{E_{\\max} \\frac{[H]_{1}^{n}}{EC_{50}^{n} + [H]_{1}^{n}}}{E_{\\max} \\frac{[H]_{0}^{n}}{EC_{50}^{n} + [H]_{0}^{n}}}$$\nThe term $E_{\\max}$ cancels, yielding:\n$$\\frac{E([H]_{1})}{E([H]_{0})} = \\frac{[H]_{1}^{n}}{[H]_{0}^{n}} \\cdot \\frac{EC_{50}^{n} + [H]_{0}^{n}}{EC_{50}^{n} + [H]_{1}^{n}}$$\nNow, we substitute the given numerical values into this expression:\n- Baseline histamine concentration: $[H]_{0} = 0.50\\,\\mu\\text{M}$\n- Post-degranulation histamine concentration: $[H]_{1} = 1.00\\,\\mu\\text{M}$\n- Half-maximal effective concentration: $EC_{50} = 0.75\\,\\mu\\text{M}$\n- Hill coefficient: $n = 2$\n\nSubstituting these values:\n$$\\frac{E([H]_{1})}{E([H]_{0})} = \\left(\\frac{1.00\\,\\mu\\text{M}}{0.50\\,\\mu\\text{M}}\\right)^{2} \\cdot \\frac{(0.75\\,\\mu\\text{M})^{2} + (0.50\\,\\mu\\text{M})^{2}}{(0.75\\,\\mu\\text{M})^{2} + (1.00\\,\\mu\\text{M})^{2}}$$\nThe units of concentration $\\mu\\text{M}$ cancel throughout the expression as expected, since the result must be dimensionless.\n$$\\frac{E([H]_{1})}{E([H]_{0})} = \\left(\\frac{1.00}{0.50}\\right)^{2} \\cdot \\frac{(0.75)^{2} + (0.50)^{2}}{(0.75)^{2} + (1.00)^{2}}$$\n$$= (2)^{2} \\cdot \\frac{0.5625 + 0.25}{0.5625 + 1.00}$$\n$$= 4 \\cdot \\frac{0.8125}{1.5625}$$\nTo avoid rounding errors, it is prudent to work with exact fractions. Let $EC_{50} = 3/4$, $[H]_0 = 1/2$, and $[H]_1 = 1$.\n$$\\frac{E([H]_{1})}{E([H]_{0})} = \\left(\\frac{1}{1/2}\\right)^{2} \\cdot \\frac{(3/4)^{2} + (1/2)^{2}}{(3/4)^{2} + (1)^{2}} = (2)^{2} \\cdot \\frac{9/16 + 1/4}{9/16 + 1} = 4 \\cdot \\frac{9/16 + 4/16}{9/16 + 16/16} = 4 \\cdot \\frac{13/16}{25/16} = 4 \\cdot \\frac{13}{25} = \\frac{52}{25}$$\nConverting the fraction to a decimal gives:\n$$\\frac{E([H]_{1})}{E([H]_{0})} = 2.08$$\nFinally, we compute $\\Delta$:\n$$\\Delta = \\frac{E([H]_{1})}{E([H]_{0})} - 1 = 2.08 - 1 = 1.08$$\nThe problem requires the answer to be rounded to four significant figures. The exact result $1.08$ has three significant figures. To express this with four, we must append a zero.\n$$\\Delta = 1.080$$\nThis represents a $108.0\\%$ increase in the vascular permeability index relative to its baseline value.",
            "answer": "$$\\boxed{1.080}$$"
        },
        {
            "introduction": "The net effect of inflammation on a tissue, such as changes in vascular tone, is often a physiological tug-of-war between opposing chemical mediators. In this problem, you will model the competing influences of prostacyclin (a vasodilator) and thromboxane A2 (a vasoconstrictor) to calculate the resulting vascular state. This exercise illustrates how the balance of signals, receptor affinities, and ligand concentrations determines the final physiological outcome. ",
            "id": "4340861",
            "problem": "In acute inflammation, endothelium-derived prostacyclin (PGI2) and platelet-derived thromboxane A2 (TXA2) exert opposing influences on vascular smooth muscle tone through G protein-coupled receptors. Assume ligand–receptor binding follows the law of mass action at steady state, giving the receptor occupancy as $$\\text{Occupancy} \\;=\\; \\frac{[L]}{K_{d} + [L]}$$ where $[L]$ is the free ligand concentration and $K_{d}$ is the equilibrium dissociation constant. Suppose the endothelial prostacyclin receptor (IP) transduces a vasodilatory signal whose amplitude scales linearly with the fraction of occupied receptors and with receptor abundance and intrinsic efficacy, so that $$S_{E} \\;=\\; \\epsilon_{\\mathrm{IP}}\\,B_{\\mathrm{IP}}\\,O_{\\mathrm{IP}}$$ where $O_{\\mathrm{IP}}$ is IP occupancy, $\\epsilon_{\\mathrm{IP}}$ is intrinsic efficacy, and $B_{\\mathrm{IP}}$ is a normalized receptor abundance factor. Similarly, the platelet thromboxane receptor (TP) transduces a vasoconstrictor signal $$S_{P} \\;=\\; \\epsilon_{\\mathrm{TP}}\\,B_{\\mathrm{TP}}\\,O_{\\mathrm{TP}}$$ where $O_{\\mathrm{TP}}$ is TP occupancy, $\\epsilon_{\\mathrm{TP}}$ is intrinsic efficacy, and $B_{\\mathrm{TP}}$ is a normalized receptor abundance factor. Define the net vascular tone index $$T \\;=\\; S_{E} - S_{P},$$ where positive values indicate net dilation and negative values indicate net constriction.\n\nIn an inflamed arteriole, local measurements estimate $[ \\mathrm{PGI2} ] = 35\\,\\mathrm{nM}$ near the endothelial surface and $[ \\mathrm{TXA2} ] = 90\\,\\mathrm{nM}$ within platelet aggregates. The corresponding receptor parameters are $K_{d,\\mathrm{IP}} = 25\\,\\mathrm{nM}$, $K_{d,\\mathrm{TP}} = 70\\,\\mathrm{nM}$, $\\epsilon_{\\mathrm{IP}} = 0.85$, $B_{\\mathrm{IP}} = 1.4$, $\\epsilon_{\\mathrm{TP}} = 1.2$, and $B_{\\mathrm{TP}} = 1.8$.\n\nUsing these values and starting from the mass-action receptor occupancy model and the linear transduction assumptions stated above, compute the net vascular tone index $T$. Express your final answer as a dimensionless number, and round your answer to four significant figures.",
            "solution": "The problem requires the calculation of the net vascular tone index, $T$, which is defined as the difference between the vasodilatory signal, $S_E$, and the vasoconstrictor signal, $S_P$. The process involves calculating each signal component separately based on the provided models and parameters, and then computing their difference.\n\nFirst, we address the vasodilatory signal, $S_E$, which is produced by prostacyclin ($\\mathrm{PGI2}$) acting on endothelial prostacyclin receptors ($\\mathrm{IP}$). The signal strength is given by:\n$$S_E = \\epsilon_{\\mathrm{IP}} B_{\\mathrm{IP}} O_{\\mathrm{IP}}$$\nwhere $\\epsilon_{\\mathrm{IP}}$ is the intrinsic efficacy, $B_{\\mathrm{IP}}$ is the receptor abundance factor, and $O_{\\mathrm{IP}}$ is the fractional receptor occupancy. The occupancy is determined by the law of mass action:\n$$O_{\\mathrm{IP}} = \\frac{[\\mathrm{PGI2}]}{K_{d,\\mathrm{IP}} + [\\mathrm{PGI2}]}$$\nThe given parameters for this system are:\n- Ligand concentration, $[\\mathrm{PGI2}] = 35\\,\\mathrm{nM}$\n- Equilibrium dissociation constant, $K_{d,\\mathrm{IP}} = 25\\,\\mathrm{nM}$\n- Intrinsic efficacy, $\\epsilon_{\\mathrm{IP}} = 0.85$\n- Receptor abundance, $B_{\\mathrm{IP}} = 1.4$\n\nWe substitute the given values into the occupancy equation for the $\\mathrm{IP}$ receptor:\n$$O_{\\mathrm{IP}} = \\frac{35}{25 + 35} = \\frac{35}{60} = \\frac{7}{12}$$\nNow, we calculate the vasodilatory signal strength, $S_E$:\n$$S_E = (0.85)(1.4)\\left(\\frac{7}{12}\\right) = (1.19)\\left(\\frac{7}{12}\\right) = \\frac{8.33}{12} \\approx 0.694167$$\n\nNext, we address the vasoconstrictor signal, $S_P$, produced by thromboxane A2 ($\\mathrm{TXA2}$) acting on platelet thromboxane receptors ($\\mathrm{TP}$). The signal strength is given by:\n$$S_P = \\epsilon_{\\mathrm{TP}} B_{\\mathrm{TP}} O_{\\mathrm{TP}}$$\nwhere $\\epsilon_{\\mathrm{TP}}$ is the intrinsic efficacy, $B_{\\mathrm{TP}}$ is the receptor abundance factor, and $O_{\\mathrm{TP}}$ is the fractional receptor occupancy. The occupancy is given by:\n$$O_{\\mathrm{TP}} = \\frac{[\\mathrm{TXA2}]}{K_{d,\\mathrm{TP}} + [\\mathrm{TXA2}]}$$\nThe given parameters for this system are:\n- Ligand concentration, $[\\mathrm{TXA2}] = 90\\,\\mathrm{nM}$\n- Equilibrium dissociation constant, $K_{d,\\mathrm{TP}} = 70\\,\\mathrm{nM}$\n- Intrinsic efficacy, $\\epsilon_{\\mathrm{TP}} = 1.2$\n- Receptor abundance, $B_{\\mathrm{TP}} = 1.8$\n\nWe substitute the given values into the occupancy equation for the $\\mathrm{TP}$ receptor:\n$$O_{\\mathrm{TP}} = \\frac{90}{70 + 90} = \\frac{90}{160} = \\frac{9}{16}$$\nNow, we calculate the vasoconstrictor signal strength, $S_P$:\n$$S_P = (1.2)(1.8)\\left(\\frac{9}{16}\\right) = (2.16)\\left(\\frac{9}{16}\\right) = \\frac{19.44}{16} = 1.215$$\n\nFinally, we compute the net vascular tone index, $T$, by subtracting the vasoconstrictor signal from the vasodilatory signal:\n$$T = S_E - S_P$$\nUsing the calculated values for $S_E$ and $S_P$:\n$$T = \\frac{8.33}{12} - 1.215 \\approx 0.694167 - 1.215 = -0.520833$$\nThe problem asks for the answer to be rounded to four significant figures. The first significant figure is the $5$. The fourth significant figure is the $8$. The following digit is $3$, which is less than $5$, so we round down (i.e., we truncate at the fourth significant figure).\n$$T \\approx -0.5208$$\nThe negative value indicates a net vasoconstrictor effect under these conditions.",
            "answer": "$$\\boxed{-0.5208}$$"
        },
        {
            "introduction": "Targeting the enzymes that produce inflammatory mediators is a cornerstone of modern therapeutic strategy. The clinical success of such drugs, like Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), often hinges on their selectivity for specific enzyme isoforms, such as COX-1 and COX-2. This exercise guides you through applying Michaelis-Menten kinetics and the principles of competitive inhibition to predict how an NSAID alters the balance of activity between these two key enzymes. ",
            "id": "4340926",
            "problem": "Arachidonic acid (AA) is converted to prostaglandin intermediates by the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Consider a cell in which both isoforms operate on the same substrate pool. Let the total flux through each isoform be the steady-state rate of product formation, which under the quasi-steady-state approximation equals the catalytic turnover of the enzyme–substrate complex. Use the following baseline parameters: for cyclooxygenase-1 (COX-1), $V_{max,1} = 120\\ \\mathrm{nmol\\,min^{-1}}$ and $K_{m,1} = 4\\ \\mathrm{\\mu M}$; for cyclooxygenase-2 (COX-2), $V_{max,2} = 150\\ \\mathrm{nmol\\,min^{-1}}$ and $K_{m,2} = 8\\ \\mathrm{\\mu M}$. The substrate concentration is $[AA] = 10\\ \\mathrm{\\mu M}$.\n\nNow introduce a Nonsteroidal Anti-Inflammatory Drug (NSAID), assumed to be a reversible competitive inhibitor with respect to AA for both isoforms, present at concentration $[I] = 5\\ \\mathrm{\\mu M}$. The inhibitor has different dissociation constants for the isoforms: $K_{i,1} = 1\\ \\mathrm{\\mu M}$ for COX-1 and $K_{i,2} = 10\\ \\mathrm{\\mu M}$ for COX-2.\n\nStarting from the fundamental scheme for enzyme catalysis $E + S \\rightleftharpoons ES \\rightarrow E + P$, and employing the quasi-steady-state approximation for $[ES]$, derive the expressions for the steady-state fluxes through COX-1 and COX-2 at baseline, and the modified fluxes in the presence of a reversible competitive inhibitor. Use these expressions to compute the baseline flux ratio $r_{b} = \\frac{v_{2}}{v_{1}}$ and the post-NSAID flux ratio $r_{a} = \\frac{v_{2}'}{v_{1}'}$, where the prime denotes inhibited conditions. Finally, compute the fold-change $F = \\frac{r_{a}}{r_{b}}$. Express $F$ as a dimensionless decimal and round your answer to three significant figures.",
            "solution": "The problem is evaluated as scientifically grounded, well-posed, objective, and complete. All necessary parameters are provided, and the question is based on fundamental principles of enzyme kinetics. Therefore, a full solution is warranted.\n\nThe problem requires the derivation of the rate equations for enzyme catalysis under baseline and competitive inhibition conditions, followed by the calculation of reaction flux ratios.\n\n**1. Derivation of the Steady-State Flux Equations**\n\nThe fundamental reaction scheme for a single-substrate enzyme is:\n$$ E + S \\underset{k_{-1}}{\\stackrel{k_1}{\\rightleftharpoons}} ES \\stackrel{k_2}{\\rightarrow} E + P $$\nwhere $E$ is the enzyme, $S$ is the substrate, $ES$ is the enzyme-substrate complex, and $P$ is the product. The rate constants for each step are $k_1$, $k_{-1}$, and $k_2$.\n\n**a. Baseline Flux (Michaelis-Menten Equation)**\n\nThe flux, $v$, is the rate of product formation:\n$$ v = \\frac{d[P]}{dt} = k_2 [ES] $$\nUsing the quasi-steady-state approximation (QSSA), we assume the concentration of the $ES$ complex is constant, i.e., $\\frac{d[ES]}{dt} = 0$. The rate of formation of $ES$ equals its rate of breakdown:\n$$ k_1 [E][S] = (k_{-1} + k_2) [ES] $$\nThe total enzyme concentration $[E]_0$ is the sum of free enzyme $[E]$ and complexed enzyme $[ES]$:\n$$ [E]_0 = [E] + [ES] \\implies [E] = [E]_0 - [ES] $$\nSubstituting $[E]$ into the steady-state equation:\n$$ k_1 ([E]_0 - [ES])[S] = (k_{-1} + k_2) [ES] $$\nRearranging to solve for $[ES]$:\n$$ k_1 [E]_0 [S] - k_1 [ES][S] = (k_{-1} + k_2) [ES] $$\n$$ k_1 [E]_0 [S] = (k_1 [S] + k_{-1} + k_2) [ES] $$\n$$ [ES] = \\frac{k_1 [E]_0 [S]}{k_1 [S] + k_{-1} + k_2} $$\nDividing the numerator and denominator by $k_1$:\n$$ [ES] = \\frac{[E]_0 [S]}{[S] + \\frac{k_{-1} + k_2}{k_1}} $$\nWe define the Michaelis constant, $K_m$, as $K_m = \\frac{k_{-1} + k_2}{k_1}$. The equation for $[ES]$ becomes:\n$$ [ES] = \\frac{[E]_0 [S]}{K_m + [S]} $$\nSubstituting this into the expression for the flux $v$:\n$$ v = k_2 [ES] = \\frac{k_2 [E]_0 [S]}{K_m + [S]} $$\nThe maximum flux, $V_{max}$, is achieved when the enzyme is saturated with substrate ($[ES] = [E]_0$), so $V_{max} = k_2 [E]_0$. This gives the final Michaelis-Menten equation for the baseline flux:\n$$ v = \\frac{V_{max} [S]}{K_m + [S]} $$\n\n**b. Flux in the Presence of a Competitive Inhibitor**\n\nA reversible competitive inhibitor, $I$, binds only to the free enzyme, forming an inactive $EI$ complex:\n$$ E + I \\rightleftharpoons EI $$\nThe dissociation constant for this equilibrium is $K_i = \\frac{[E][I]}{[EI]}$.\nThe total enzyme concentration is now distributed among three species:\n$$ [E]_0 = [E] + [ES] + [EI] $$\nFrom the inhibitor equilibrium, we have $[EI] = \\frac{[E][I]}{K_i}$. Substituting this into the mass balance:\n$$ [E]_0 = [E] \\left(1 + \\frac{[I]}{K_i}\\right) + [ES] $$\nThe QSSA for $[ES]$ remains unchanged: $k_1 [E][S] = (k_{-1} + k_2) [ES]$, which gives $[E] = \\frac{K_m}{[S]}[ES]$.\nSubstituting this expression for $[E]$ into the mass balance equation:\n$$ [E]_0 = \\frac{K_m}{[S]}[ES] \\left(1 + \\frac{[I]}{K_i}\\right) + [ES] $$\n$$ [E]_0 = [ES] \\left[ \\frac{K_m}{[S]} \\left(1 + \\frac{[I]}{K_i}\\right) + 1 \\right] $$\n$$ [E]_0 = [ES] \\frac{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S]}{[S]} $$\nSolving for $[ES]$:\n$$ [ES] = \\frac{[E]_0 [S]}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S]} $$\nThe inhibited flux, $v'$, is $v' = k_2 [ES]$. Substituting the expression for $[ES]$ and using $V_{max} = k_2 [E]_0$:\n$$ v' = \\frac{V_{max} [S]}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S]} $$\nThis is the expression for the flux in the presence of a reversible competitive inhibitor.\n\n**2. Calculation of Fluxes and Ratios**\n\nThe given parameters are:\nSubstrate concentration: $[S] = [AA] = 10\\ \\mathrm{\\mu M}$.\nInhibitor concentration: $[I] = 5\\ \\mathrm{\\mu M}$.\nCOX-1: $V_{max,1} = 120\\ \\mathrm{nmol\\,min^{-1}}$, $K_{m,1} = 4\\ \\mathrm{\\mu M}$, $K_{i,1} = 1\\ \\mathrm{\\mu M}$.\nCOX-2: $V_{max,2} = 150\\ \\mathrm{nmol\\,min^{-1}}$, $K_{m,2} = 8\\ \\mathrm{\\mu M}$, $K_{i,2} = 10\\ \\mathrm{\\mu M}$.\n\n**a. Baseline Fluxes ($v_1$, $v_2$) and Ratio ($r_b$)**\n\nThe baseline flux for COX-1 is:\n$$ v_1 = \\frac{V_{max,1} [S]}{K_{m,1} + [S]} = \\frac{120 \\times 10}{4 + 10} = \\frac{1200}{14} = \\frac{600}{7}\\ \\mathrm{nmol\\,min^{-1}} $$\nThe baseline flux for COX-2 is:\n$$ v_2 = \\frac{V_{max,2} [S]}{K_{m,2} + [S]} = \\frac{150 \\times 10}{8 + 10} = \\frac{1500}{18} = \\frac{250}{3}\\ \\mathrm{nmol\\,min^{-1}} $$\nThe baseline flux ratio is:\n$$ r_b = \\frac{v_2}{v_1} = \\frac{250/3}{600/7} = \\frac{250}{3} \\times \\frac{7}{600} = \\frac{25 \\times 7}{3 \\times 60} = \\frac{35}{36} $$\n\n**b. Post-NSAID Fluxes ($v_1'$, $v_2'$) and Ratio ($r_a$)**\n\nFirst, we calculate the inhibition factor $\\alpha = \\left(1 + \\frac{[I]}{K_i}\\right)$ for each isoform.\nFor COX-1:\n$$ \\alpha_1 = 1 + \\frac{[I]}{K_{i,1}} = 1 + \\frac{5}{1} = 6 $$\nFor COX-2:\n$$ \\alpha_2 = 1 + \\frac{[I]}{K_{i,2}} = 1 + \\frac{5}{10} = 1.5 $$\nThe inhibited flux for COX-1 is:\n$$ v_1' = \\frac{V_{max,1} [S]}{K_{m,1}\\alpha_1 + [S]} = \\frac{120 \\times 10}{4 \\times 6 + 10} = \\frac{1200}{24 + 10} = \\frac{1200}{34} = \\frac{600}{17}\\ \\mathrm{nmol\\,min^{-1}} $$\nThe inhibited flux for COX-2 is:\n$$ v_2' = \\frac{V_{max,2} [S]}{K_{m,2}\\alpha_2 + [S]} = \\frac{150 \\times 10}{8 \\times 1.5 + 10} = \\frac{1500}{12 + 10} = \\frac{1500}{22} = \\frac{750}{11}\\ \\mathrm{nmol\\,min^{-1}} $$\nThe post-NSAID flux ratio is:\n$$ r_a = \\frac{v_2'}{v_1'} = \\frac{750/11}{600/17} = \\frac{750}{11} \\times \\frac{17}{600} = \\frac{75 \\times 17}{11 \\times 60} = \\frac{5 \\times 17}{11 \\times 4} = \\frac{85}{44} $$\n\n**c. Fold-Change in Flux Ratio ($F$)**\n\nThe fold-change $F$ is the ratio of the post-NSAID flux ratio to the baseline flux ratio:\n$$ F = \\frac{r_a}{r_b} = \\frac{85/44}{35/36} = \\frac{85}{44} \\times \\frac{36}{35} $$\nSimplifying the fraction:\n$$ F = \\frac{(5 \\times 17)}{(4 \\times 11)} \\times \\frac{(4 \\times 9)}{(5 \\times 7)} = \\frac{17 \\times 9}{11 \\times 7} = \\frac{153}{77} $$\nTo obtain the final decimal value, we perform the division:\n$$ F = \\frac{153}{77} \\approx 1.9870129... $$\nRounding to three significant figures, we get:\n$$ F \\approx 1.99 $$\nThis result indicates that the inhibitor is selective for COX-1, causing the flux ratio of COX-2 to COX-1 to approximately double.",
            "answer": "$$\\boxed{1.99}$$"
        }
    ]
}